Targeting human CD2 by the monoclonal antibody CB.219 reduces intestinal inflammation in a humanized transfer colitis model.pdf.pdf

Clinical Immunology (2015) 157,16–25
available at
Clinical Immunology
ate/yclim
Targeting human CD2 by the monoclonal
antibody reduces intestinal
inflammation in a humanized transfer
colitis model
Ulrike Erben a, Nina N. Pawlowski a,1, Katja Doerfel a,2,
Christoph Loddenkemper b,3, Jörg C. Hoffmann c,
Britta Siegmund a, Anja A. Kühl a,⁎
a Department of Medicine I–Gastroenterology, Infectious Diseases and Rheumatology and Research Center ImmunoSciences,
Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin D-12203, Germany
b Institute of Pathology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30,
Berlin D-12203, Germany
c Department of Medicine I, St. Marienkrankenhaus, Salzburger Straße 15, Ludwigshafen D-67067, Germany
Received 12 May 2014; accepted with revision 2 January 2015
Available online 14 January 2015
KEYWORDS Abstract The cell adhesion molecule CD2 facilitates antigen-independent T-cell activation
Human CD2; and CD2 deficiency or blockade reduces intestinal inflammation in murine models. We here
IBD mouse model; aimed to evaluate the therapeutic potential of monoclonal antibodies (mAb) specific for human
Transfer colitis; CD2 in colitis treatment. Transfer colitis induced by naïve CD4+ T cells expressing human CD2
Monoclonal antibody was treated with anti-human CD2